This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genzyme: Analysts' Upgrades, Downgrades

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Acorda Therapeutics (ACOR) downgraded at Leerink from Outperform to Market Perform. Valuation call, as potential risks lay ahead.

American Eagle (AEO - Get Report) upgraded at Wells from Market Perform to Outperform. Estimates also raised, to reflect the company's comp sales momentum.

Baker Hughes (BHI - Get Report) reinstated at BofA/Merrill. BHI coverage reinstated with a Buy rating and $61 price target. HBI has above average exposure to higher growth, early cycle product service lines.

Cameron International (CAM) reinstated at BofA/Merrill. CAM coverage reinstated with a Buy rating and $56 price target. Upside from integration of NATCO acquisition, Bank of America/Merrill Lynch said.

Core Labs (CLB) initiated at BofA/Merrill. CLB coverage initiated with a Buy rating and $136 price target. Buy based on continuation of share buybacks, valuation, and earnings acceleration.

Citrix Systems (CTXS) rated new Neutral at UBS. Coverage of CTXS was started with a Neutral rating. $47 price target. Stock is already pricing in increased IT spending.

Deere (DE - Get Report) upgraded at JP Morgan from Neutral to Overweight. $65 price target. Seeing signs of a recovery in multiple areas of equipment.

Deere (DE - Get Report) estimates, target increased at UBS. Shares of DE now seen reaching $61. Estimates also raised, because of higher expected agriculture demand. Neutral rating.

Dril-Quip (DRQ) initiated at BofA/Merrill. DRQ coverage initiated with a Buy rating and $68 price target. Recent capacity expansion is driving revenue growth.

FMC Technologies (FTI) reinstated at BofA/Merrill with an Underperform rating and $65 price target. Not many growth catalysts and poor valuation, Bank of America/Merrill Lynch said.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AEO $16.92 -0.24%
AMAT $21.76 1.26%
BHI $68.34 2.03%
DE $88.90 1.59%
HPQ $33.41 2.71%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs